Drug addiction has been associated with deficits in mesostriatal dopamine (DA) function, but whether this state extends to behavioral addictions such as pathological gambling (PG) is unclear. Here we used positron emission tomography and the D 3 receptor-preferring radioligand [
INTRODUCTION
Pathological gambling (PG) is a psychiatric disorder that afflicts 0.2-5.3% of the population worldwide. 1 Long characterized as a behavioral addiction, PG has now been formally re-classified with substance dependence in the fifth edition of the psychiatric Diagnostic and Statistical Manual, reflecting extensive overlap in symptom profiles and shared risk. [2] [3] [4] Despite their phenomenological similarities, common neurobiological underpinnings are only beginning to be explored.
Positron emission tomography (PET) and single-photon emission computerized tomography studies with dopamine (DA) D 2 5, 6 methamphetamine, 7 heroin 8 and alcohol 9 dependence are associated with a hypodopaminergic state indexed experimentally by a blunted DA response to an amphetamine or methylphenidate challenge. The significance of this deficit in DA transmission and whether it is the result of drug use or a predating vulnerability has not been fully elucidated. However, low levels of DA in substance use disorders have been linked to core clinical features and maladaptive behaviors, which are also shared by behavioral addictions and, as such, could also be a feature of PG. For example, a blunted dopaminergic response to amphetamine has been associated with compulsive use (choice to self-administer cocaine in a laboratory model 6 ), relapse (in a treatment setting 7, 10 ) and to craving. 5 Whether disrupted DA transmission can explain these key features of PG, including compulsive pursuit of reward, is unknown.
In sharp contrast with the human in vivo neuroimaging literature, decades of preclinical data in animal models of addiction have shown that compulsive drug (or reward) seeking is associated with greater DA release to amphetamine. Specifically, in rodents, repeated intermittent exposure to drugs of abuse (or stress) is associated with a greater locomotor response and DA release upon re-exposure to drug. This phenomenon, known as sensitization, is a critical form of neuroplasticity believed to enhance the salience of a reward and thereby promote seeking, 11 and which has been associated with an upregulation of DA D 3 receptors. 12 With regards to the last point, a growing body of work, which includes our own finding of increased D 3 receptor levels in substantia nigra (SN) of stimulant users, 13, 14 suggests that D 3 upregulation could be a feature of addiction and/or related to the addiction phenotype. In the current study, we sought to investigate whether level of this receptor was related to the status of DA transmission.
One of the reasons for the discrepancy between human and preclinical literature (reviewed elsewhere 15, 16 ) could be that chronic exposure to drugs in substance-addicted individuals (vs intermittent exposure in rodent sensitization literature) results in an enduring depletion of DA, caused by presynaptic DA cell injury (for example, see refs [17] [18] [19] . Indirect support for this possibility 1 Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, ON, Canada; comes from a PET study showing that, in contrast to drugaddicted individuals, healthy volunteers exposed to an intermittent low-dose amphetamine regimen, exhibit significantly greater amphetamine-induced striatal DA release (interpreted as sensitization) associated with greater psychomotor effects of the drug, which was predicted by trait impulsiveness. 20 Notably, the 'sensitizing' regimen in that study was not associated with a change in DA D 2/3 receptor levels, in contrast with the consistent finding of low striatal D 2/3 receptor levels in addiction.
Investigations of DA mechanisms in PG have shown ventral striatal DA release to large rewards during gambling tasks, which related to symptom severity, self-reported 'high' and self-reported 'excitement'. [21] [22] [23] [24] Similarly, patients with Parkinson's disease (PD) with medication-induced PG displayed significantly greater DA release during a gambling-like task than PD patients without PG. 25 Of note, we and others have recently reported that in PG, D 2/3 receptor levels are also within normal range in all functional regions of the striatum and midbrain. 26, 27 Together, these results indirectly support the possibility that PG without co-morbid drug abuse may not be associated with a 'blunted' DA transmission but may instead be associated with an increased DA response, which could be linked to compulsive pursuit of reward.
The present study tested the hypothesis in stimulant-naive men diagnosed with PG and healthy non-PG controls that PG, a behavioral addiction, is associated with greater DA release to amphetamine. DA release was indexed by displacement of the D 3 preferring radioligand, [
MATERIALS AND METHODS Subjects
All procedures were approved by the Centre for Addiction and Mental Health Research Ethics Board and complied with ethical standards of the Helsinki Declaration. Volunteers (13 non-treatment-seeking males with PG and 12 healthy control (HC) males matched for age, education and cigarette smoking status) were recruited by advertisements and gave written informed consent. Inclusion/exclusion criteria have been described in a previous report. 27 Briefly, PG subjects were required to meet Diagnostic and Statistical Manual of Mental Disorder (DSM-IV) criteria for PG and demonstrate current clinically relevant levels of PG severity as per a DSM-IV-based questionnaire (DSM-IV-Q) 29 and the South Oaks Gambling Scale (SOGS). 30 Conversely, HC subjects were required to score 0 on the DSM-IV-Q and SOGS. In addition, all subjects met the following criteria: (1) no medications or significant medical conditions; (2) 34 based on previous use of this measure to characterize pathological gamblers. [35] [36] [37] Subjects also took part in a 15-min gambling session (see Supplementary Information; details and results have been published previously), 27 during which they reported on subjective experience via visual analog scales.
On a separate day, subjects, not blind to the procedure, completed two identical PET scans in fixed order (to avoid a conditioned response to the scanning environment) 38 with the radiotracer [ , a time at which behavioral effects of amphetamine are peaking and blood levels are on the ascending phase (peak blood levels are typically achieved 3-4 h. 39 This interval has been shown by our group to lead to robust changes in 42 ; Drug Effects Questionnaire) and visual analog scale ratings of energy and desire to gamble. Heart rate and blood pressure were monitored at 15-min intervals, and blood was drawn to measure plasma cortisol and amphetamine levels.
PET imaging [ 11 C]-( þ )-PHNO synthesis and image acquisition protocols on the CPS-HRRT neuro-PET camera system (Siemens Medical Imaging, Knoxville, TN, USA) are described in detail elsewhere. 13 Scans were initiated following bolus injection of [ 
Data analysis
Physiological and Subjective Measures. Blood samples were analyzed for levels of plasma amphetamine and cortisol by the CAMH Clinical Laboratory. Statistical analysis of physiological and subjective measures was performed using repeated-measures analysis of variances and t-tests. Post-amphetamine maximum or minimum values were used for measures with repeated time points.
PET Region-of-Interest Analysis. ROI delineation and time activity curve analyses were performed using ROMI (details in Rusjan et al. 43 ). Functional sub-compartments of the striatum 44 including the associative striatum (AST), limbic striatum (LST) and sensorimotor striatum (SMST) were chosen as ROIs. Delineation for the globus pallidus (GP; whole) and SN (an area where 100% of [
11 C]-( þ )-PHNO binding is associated with D 3 receptor levels) 45 is described elsewhere. 46 was estimated in each ROI using the simplified reference tissue method (SRTM), 47 with cerebellar cortex (excluding vermis and lobules IX and X) as reference region. Parameter estimation was performed using PMOD (Version 2.8.5; PMOD Technologies Ltd, Zurich, Switzerland). Percent change in BP ND after amphetamine challenge was calculated. Group comparisons of these values were conducted using standard repeated-measures analysis of variances and Kruskal-Wallis H-tests (for non-parametric data). When appropriate, Least Significant Difference t-tests, Bonferroni corrected, were applied.
Relationships between percent changes in BP ND and changes in subjective/physiological measures were calculated using linear regression (with baseline scores as covariates). We also investigated the relationship between the magnitude of change in [ 11 C]-( þ )-PHNO BP ND and D 3 receptor levels (BP ND in SN during baseline scan 45 ) based on previous work indicating a link between D 3 upregulation, addiction 13 and dopaminergic sensitization. 12 Relationships to trait measures and behavior during the gambling episode were assessed using Pearson correlation.
PET Voxel-wise Analysis. Voxel-wise parameter estimation of [ 11 C]-( þ )-PHNO BP ND was implemented using RPM. 48 Normalized BP ND maps were investigated to assess significant contrasts between conditions using paired t-tests under SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK). An implicit mask was applied removing voxels with BP ND values o0.1. The threshold for significant clusters was set to a family-wise error corrected Po0.05.
RESULTS

Subject characteristics and traits
Of the 13 PG and 12 HC subjects, one per group was lost during scanning, resulting in a final sample of 12 PG and 11 HC. Subject characteristics are summarized in Table 1 (see also previous publication 27 ).
Physiological and subjective effects of amphetamine Detailed physiological and subjective data are presented in Table 2 . Overall amphetamine increased physiological outcome Dopamine release in pathological gambling I Boileau et al (heart rate and blood pressure), plasma levels of amphetamine and cortisol, self-reported effects of amphetamine (Addiction Research Center Inventory, Drug Effects Questionnaire) and desire to gamble (visual analog scale) but this did not differ between groups. Desire to gamble was greater in PG vs HC, and increased with amphetamine (vs baseline), but there was no interaction; confidence in ability to refrain from gambling showed the opposite pattern (PGoHC and amphetamineobaseline). Cortisol levels were greater in HC relative to PG but there was no interaction.
PET measures
There was no significant effect of group or condition on [ 11 C]-( þ )-PHNO mass injected, dose and specific activity (all P40.1).
Between-group differences in regional [
11 C]-( þ )-PHNO binding at baseline are detailed in another report. 27 Following amphetamine, [ 11 C]-( þ )-PHNO binding was decreased, indicative of DA release, in all ROIs in both groups (ROI Â condition F(4, 84) ¼ 5.1; P ¼ 0.001), ranging from a maximum of À 36 ± 22% in SN to a minimum of À 16 ± 7% in AST; percent change in [ 11 C]-( þ )-PHNO BP ND in other ROIs was À 24±11% in LST, À 23±11% in SMST and À 18±14% in GP (all Po0.001; Figure 1 ).
Comparing percent change in [ 11 C]-( þ )-PHNO BP ND between groups (Figures 1 and 2) , we found greater percent change after amphetamine in PG than HC in striatal ROIs (ROI Â group F(3,19) ¼ 4.12, P ¼ 0.02), in line with our hypothesis. This effect corresponded to a 63% (P ¼ 0.01) and 54% (P ¼ 0.05) difference in [ 11 C]-( þ )-PHNO BP ND change in PG relative to HC in AST and SMST, respectively, and marginally greater [
11 C]-( þ )-PHNO BP ND change (63%, P ¼ 0.07) in GP. In LST and SN, [ 11 C]-( þ )-PHNO BP ND change was, respectively, 7% lower and 29% greater in PG than HC, but these effects did not reach statistical significance (P40.1). Controlling for baseline BP ND showed that baseline values were significant covariates in SMST (P ¼ 0.03) and GP (P ¼ 0.03), but did not change the group differences in these regions (AST P ¼ 0.01, SMST P ¼ 0.03, GP P ¼ 0.03). In addition, controlling for potential differences in depressive symptomatology (BDI, HAM-D scores) and alcohol use did not change the significant ROI Â group interaction (all Po0.05).
Voxel-wise analysis confirmed ROI findings, showing that amphetamine significantly decreased 27 ). This result indicated that higher D 3 receptor availability in SN was associated with greater DA release in LST, and predicted severity of the addiction (see Figure 3) .
DISCUSSION
To our knowledge, this study provides the first neuroimaging evidence of an elevated DA response to a stimulant challenge in otherwise healthy, stimulant-naive PG, suggesting greater DA release (vs a 'blunted' response 5, 6 ) in putatively addicted individuals. These results indicate that despite their overlapping clinical features, dopaminergic mechanisms may contribute differentially to behavioral vs substance addictions, or that greater dopaminergic transmission is differentially discernible in behavioral addictions free of potential substance-specific confounds. In addition, the data support preclinical and recent human data pointing to a putative role for the D 3 receptor in the addiction phenotype. 11 C]-( þ )-PHNO, indicating dopamine release, was observed in all regions of interest, and percent change in binding potential (BP ND ) was significantly more negative in PG (light circles) than HC (dark circles) in associative striatum (AST) and sensorimotor striatum (SMST); *Po0.05. The same pattern was observed in globus pallidus (GP) and substantia nigra (SN), but the difference did not reach statistical significance. LST, limbic striatum.
Our neuroimaging finding of exaggerated DA response to amphetamine in PG is in line with the 'incentive sensitization' model of addiction. 11 The model posits that compulsive 'reward seeking' in addiction involves long-lasting changes within the brain's DA circuitry normally involved in incentive motivation, rendering it hypersensitive to drug and non-chemical reward and thus driving exaggerated approach behaviors. In addition to a wealth of evidence for sensitization to drugs, preclinical work also supports the view that non-drug rewards can lead to sensitization. Specifically, increased 'incentive salience attribution' and 'compulsive pursuit' have been demonstrated for food and sexual partners. 50 Interestingly, a recent study, 51 reported that chronic exposure to unpredictable reinforcement (saccharine), a model of gambling, leads to amphetamine sensitization in rats. The authors concluded that repeated exposure to gambling-like conditions could induce neuroadaptations in DA transmission similar to those produced by amphetamine exposure, and may account for the development of gambling addiction. This is not to say that greater DA release in PG, indexed here by amphetamine-induced change in [ 11 C]-( þ )-PHNO BP ND , may not have existed (as a vulnerability factor) before the onset of problematic gambling, nor does it exclude the possibility that in substance use disorder, sensitization could have acted in the initial phase of the disorder and then become masked or extinguished by chronic drug use.
In contrast to the preclinical literature, neuroimaging data supporting a hyper dopaminergic state have been sparse in humans with a behavioral addiction, and inconsistent in those with a chemical addiction. With regard to behavioral addiction, previous neuroimaging studies in patients with medicated PD exhibiting a range of impulse control disorders (ICDs; including PG) have provided some evidence of DA system hypersensitivity associated with addiction-like behaviors. Specifically, these PET/[
11 C]raclopride studies have shown that relative to their counterparts without ICD, patients with ICD have enhanced DA release in LST in response to rewarding stimuli, 52 to a gambling task 25 and to their dopaminergic medication. 53 As well, functional magnetic resonance imaging studies present seemingly parallel, although indirect findings showing increased reward-related blood-oxygen level-dependent activity in the ventral striatum in patients with ICD. 54 Although these findings suggest that the pathological pursuit of natural rewards or appetitive cues may be modulated by neuroadaptations within the DA system, it is possible that the observed effects are attributable to conditioned responses to reward-related cues (that is, gambling-associated stimuli). In contrast, our study provides direct evidence that the hyper-dopaminergic response can also be observed in response to pharmacological challenge-a stimulus with which these PG subjects had no conditioning history.
Our results are in striking contrast with the accepted finding that drug addiction is associated with a hypodopaminergic sate, characterized by blunted [
11 C]raclopride displacement following amphetamine or methylphenidate. 55 Although [ 11 C]-( þ )-PHNO has been shown to be more sensitive to changes in endogenous DA levels (in the current study and in previous published work 56 ), which could have helped in detecting between-group differences, we do not believe that the discrepancy between the current finding and the reports of blunted DA release in drug addiction can be explained by choice of radioligand. In a previous study with these subjects, we report binding of both the D 3 preferring agonist [
11 C]-( þ )-PHNO and the antagonist [ 11 C]raclopride within control range, suggesting that differences in D 3 or high affinity D 2/3 receptors are unlikely to explain the present findings. 27 One likely explanation for the discrepancy between the current finding and those reported in chemical addiction is that 'expression of sensitization' in substance-addicted individuals may be masked by an extensive depletion of DA stores during early withdrawal, as evidenced by both animal models and human brain data. 55, 57 In this regard, most PET studies looking at amphetamine-triggered DA release (PET/[
11 C]raclopride) have measured neurochemical outcomes at least 14 days after exposure to drug. 15 This drug-free interval is perhaps sufficient to avoid residual effects of drugs, but it may not be long enough to allow recovery, if any, of DA stores. Although there is no consensus on whether chronic exposure to drugs in humans is associated with neurotoxicity, the possibility that damage to DA neurons can explain failure to find a hyperdopaminergic response (similar to that observed in animals) cannot be entirely ruled out. The literature in animals suggests that this may be the case, as neurotoxic regimens of high-dose amphetamine are not associated with sensitization. 17 With respect to the regional distribution of our findings, previous imaging studies reported a greater dopaminergic response in the ventral LST, in agreement with microdialysis studies of the nucleus accumbens. 11 However, 'dopaminergic sensitization' affecting dorsal striatum has also been reported in human 20, 58 and animals studies, 11 and in the current study, we find that the greater dopaminergic response in PG vs HC is expressed in the dorsal striatum, an area which interestingly has been linked with sensitization in healthy humans 20 and in patients with schizophrenia. 59 This area is traditionally believed to be involved in 'habit formation' as addiction takes hold, 60 but has also more recently been implicated in incentive salience processes. Here we find that in PG, greater DA release in dorsal striatum is related to faster rate of play and smaller bet size on the slot machine, a strategy that maximizes number of spins. Speed of play has previously been found to contribute to the perceived reinforcing effects of slot machines in PG, 61 and might be interpreted as hyperlocomotion, which accompanies amphetamine sensitization in rats. With regard to the ventral striatum, it is interesting to note that several individual differences were found in this region (correlations), despite a lack of group differences in DA release. For example, we found that DA release related to gambling severity (SOGS scores) in PG subjects, suggesting that although greater DA was only evident in dorsal regions, DA release in LST may still contribute to progressive severity of the disorder; this suggests that ventral striatal findings may capture individual differences in reward-based decision making, rather than an overall index of habitual/compulsive responding (see, for example, Everitt and Robbins 62 ). The lack of overall group difference in LST (a smaller, noisier striatal ROI prone to partial volume effect) does not appear to be a statistical artifact, given that effect size for the group difference in this region was small, Cohen's d ¼ 0.14. It could equally be argued that greater neurochemical response to the amphetamine challenge is a risk phenotype, which predates exposure to appetitive stimuli (drugs or other) and, in some cases, can lead to addictive-like behaviors. In agreement with this, a number of studies in non-addicted individuals have reported a link between greater amphetamine-triggered DA release and trait impulsiveness. 63 Although this suggests that between-group differences in impulsiveness in the current study could partly explain the finding, we found that, unlike severity of the addiction (SOGS), impulsiveness (Eysenck Impulsiveness Scale) scores were not related to dopaminergic response to amphetamine in any of the striatal subregions. Furthermore, our finding of greater DA release in PG did not appear to be driven by trait impulsiveness, as controlling for impulsiveness scores yielded a similar effect.
The second critical finding in this study is the relationship between amphetamine-induced striatal DA release and D 3 receptor levels. The D 3 receptor, first described by Sokoloff 64 as having a unique mesocorticolimbic distribution, has been investigated as a drug-addiction target based on convincing evidence that D 3 antagonism decreases addiction-relevant behaviors in animals. 49 The present finding that D 3 receptor levels (indexed by SN [
11 C]-( þ )-PHNO BP ND ) predict LST DA response to amphetamine as well as severity of the syndrome (SOGS scores), suggests that D 3 levels may serve as an early marker of PG vulnerability. This is in line with preclinical studies 49 and with our recent work in humans linking D 3 receptor levels to features of the addiction phenotype. 13, 14, 27 It is also in direct agreement with some, although not all, animal studies suggesting that D 3 receptor levels are critical to the development of dopaminergic sensitization. 49 Reports linking D 3 receptor level and occurrence of dopaminergic sensitization have not measured D 3 in the SN and only report D 3 upregulation in striatum. 12, 65 Note that in the current study we are limited to pre-and post-synaptic D 3 receptors measured in the SN as an index of D 3 levels 45 and thus do not know whether this finding is region specific or occurs in other regions (for example, striatum). Furthermore, this method also does not allow a distinction between hetero-and autoreceptors. Pharmacological studies conducted with D 3 ligands (most nonspecific to D 3 but some with higher potency for D 3 (SB-277011-A)), seem to contradict the view that D 3 receptors are involved in increased DA transmission by showing an inhibitory effect of D 3 receptor agonism on DA release. 66 Antisense and gene knockout studies collectively suggest that D 2 auto-receptors appear to be the primary mediators of inhibitory control of DA release, whereas D 3 receptors may contribute only indirectly (via DA transport). 67 This view appears to be supported by the finding of a relationship between lower D 2/3 receptor levels measured with [ 18 F]fallypride (presumably D 2 auto-receptors) and increased DA release. 63 Currently, the exact role and conditions in which D 3 receptors modulate DA transmission or whether this effect is through auto-receptors (whose function is still elusive 68 ), or hetero-receptors, remain unknown. We therefore emphasize that whether our finding of a relationship between D 3 receptor levels, DA release, and gambling severity are causally/mechanistically linked will need to be established in future studies.
A surprising result was that of plasma cortisol levels, which (although increased by amphetamine as expected) was significantly lower in PG than HC at both baseline and post-amphetamine time points. This finding is difficult to interpret, given that the literature on cortisol in PG is inconsistent and often shows no difference from controls, [69] [70] [71] but is in line with a report of hypoactive HPA response in pathological vs recreational gamblers. 72 Our results should be interpreted in light of the following limitations. For one, the study was carried out in a small sample composed of only men; however, this gender homogeneity combined with the absence of comorbid psychiatric conditions enabled us to characterize PG in the absence of moderating factors or potential confounds. Other caveats include the use of a ligand that is selective to D 3 receptors only in the SN, hence, limiting our D 3 finding to this region. Other generic limitations of using this ligand include scanning at non-tracer doses, the possibility of carryover effects from the first [
11 C]-( þ )-PHNO scan to the second (reducing the power to find additional effects), and specific binding in the reference tissue-for a detailed discussion of these issues refer to Shotbolt et al. 56 In this regard, a previous study investigating the confound of carry-over effect on [ 11 C]-( þ )-PHNO BP ND did not detect a difference between same-day and separate-day procedures but did note that the magnitude of displacement tended to be greater for same-day vs different-day scans (for example, in the LST À 22% vs À 20%; SMST; À 18% vs 14%). 56 Regardless, the carry-over confound should not affect the between-group difference or within-group correlational findings in PG because all subjects were scanned twice on the same day. Further, we did not find that PG reported greater subjective effects of amphetamine than HC, although increased DA response in LST was associated with decreased confidence to refrain from gambling after amphetamine. One reason for the general dearth of effects may be that the highly restrictive environment (PET camera) together with the negative side effects of [
11 C]-( þ )-PHNO itself (queasiness, nausea felt by some, although not most, individuals) obscured group differences in the mood-related effects of amphetamine.
Despite these limitations, our data help to elucidate the role of dopaminergic mechanisms in behavioral addictions such as PG, suggesting that dopaminergic sensitization in dorsal striatum, along with D 3 -linked ventral striatal mechanisms, influence gambling behavior and severity of the pathology. At the clinical level, the present findings suggest that dopaminergic sensitization may mediate enhanced response to both chemical and nonchemical rewards, contributing to the high prevalence of substance addictions in PG. 73 More fundamentally, the present data are consistent with the pivotal role of neuroplasticity in addictive pathology, 74 and corroborate early claims that many environmental stimuli apart from drugs can produce sensitization. 75 By extension, the data also support the view that sensitization of the DA system may have a role in (at least the early phases of) substance addiction in humans, whose expression may, however, be masked by a progressive DA deficiency.
